Verberne Hein J, van der Spank Aukje, Bresser Paul, Somsen G Aernout
Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam;
Heart Int. 2012 Jun 5;7(2):e13. doi: 10.4081/hi.2012.e13. Epub 2012 Jun 19.
The aim of this study was to evaluate the prognostic value of renal function in relation to amino-terminal portion of the pro-hormone B-type natriuretic peptide (NT-proBNP) and parameters of cardiopulmonary exercise testing in predicting mortality and morbidity in patients with moderate chronic heart failure (CHF). Sixty-one CHF patients were included in the study. Patients' characteristics were: age 64.3±11.6 years; New York Heart Association class I/II/III: 14/37/10; left ventricular ejection fraction: 0.30±0.13 (%); NT-proBNP: 252.2±348.0 (ng/L); estimated creatinine clearance (e-CC): 73.6±31.4 (mL/min); estimated glomerular filtration rate (e-GFR): 66.1±24.6 (mL/min/1.73 m(2)); the highest O2 uptake during exercise (VO(2-peak)): 1.24±0.12 mL/kg/min; VO(2)/workload: 8.52±1.81 (mL/min/W)]. During follow up (59.5±4.0 months) there were 15 cardiac deaths and 16 patients were hospitalized due to progression of heart failure. NT-proBNP and VO(2)/workload were independently associated with cardiac death (P=0.007 and P=0.006, respectively). Hospitalization for progressive CHF was only associated with NT-proBNP (P=0.002). The combined cardiac events (cardiac death and hospitalization) were associated with NT-proBNP and VO(2)/ workload (P=0.007 and P=0.005, respectively). The addition of estimates of renal function (neither serum creatinine nor e-GFR) did not improve the prognostic value for any of the models.In conclusion, in patients with moderate CHF, increased NT-proBNP and reduced VO(2)/ work-load identify those with increased mortality and morbidity, irrespective of estimates of renal function.
本研究旨在评估肾功能与前体激素B型利钠肽(NT-proBNP)氨基末端部分以及心肺运动试验参数在预测中度慢性心力衰竭(CHF)患者死亡率和发病率方面的预后价值。61例CHF患者纳入本研究。患者特征如下:年龄64.3±11.6岁;纽约心脏协会心功能分级I/II/III级:14/37/10;左心室射血分数:0.30±0.13(%);NT-proBNP:252.2±348.0(ng/L);估算肌酐清除率(e-CC):73.6±31.4(mL/min);估算肾小球滤过率(e-GFR):66.1±24.6(mL/min/1.73 m²);运动期间最高摄氧量(VO₂峰值):1.24±0.12 mL/kg/min;VO₂/工作量:8.52±1.81(mL/min/W)。随访期间(59.5±4.0个月),有15例心源性死亡,16例患者因心力衰竭进展而住院。NT-proBNP和VO₂/工作量与心源性死亡独立相关(分别为P = 0.007和P = 0.006)。因进行性CHF住院仅与NT-proBNP相关(P = 0.002)。联合心脏事件(心源性死亡和住院)与NT-proBNP和VO₂/工作量相关(分别为P = 0.007和P = 0.005)。添加肾功能评估指标(血清肌酐和e-GFR均未改善)对任何模型的预后价值均无改善。总之,在中度CHF患者中,NT-proBNP升高和VO₂/工作量降低可识别出死亡率和发病率增加的患者,而与肾功能评估无关。